Incanthera's (LON:INC) Simon Ward and Tim McCarthy speak to Proactive following the release of their interim results for the six months ended 30 September 2020.
McCarthy explains how it has been a 'pivotal year' for the company and says they're now fully focused on further development of its skin cancer asset, Sol, which is making great progress towards commercialisation.
Ward says the development of Sol has gone 'way beyond any expectations' especially given the difficult year externally. He reminds our audience about the qualities of this treatment, which he says in comparison with competitors 'knocks them out of the park'.
In terms of commercialisation of Sol, McCarthy says 'there are conversations going on as we speak' and looks 'very promising'.